Markets
In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on NeuBase Therapeutics (NBSE – Research Report), with a price target of $17.00. The company’s shares closed last Monday at $5.70, close to its 52-week low of $5.42.
According to TipRanks.com, Singh is a 5-star analyst with an average return of 15.4% and a 47.6% success rate. Singh covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Catabasis Pharmaceuticals, and Vertex Pharmaceuticals.
NeuBase Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.33.
The company has a one-year high of $12.89 and a one-year low of $5.42. Currently, NeuBase Therapeutics has an average volume of 323.4K.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Arena Pharmaceuticals, Inc (NASDAQ:ARNA) - The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) - The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock, at a price to the public of $5.00 per share. The gross proceeds to NeuBase from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by NeuBase, are expected to be approximately $40 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. In addition, NeuBase has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares of common stock in the offering are being sold